Collectively, their findings suggest that the new proliferative factor REG1A, which is regulated by IL-6/IL-22-JAK-STAT3 signaling, may represent an attractive therapeutic target for patients with inflammatory bowel disease (Mao et al., 2021). This evidence concerns the gene STAT3 and inflammatory bowel disease.